 | Up a level |
Hehlmann, Rüdiger; Voskanyan, Astghik; Lauseker, Michael; Pfirrmann, Markus; Kalmanti, Lida; Rinaldetti, Sebastien; Kohlbrenner, Katharina; Haferlach, Claudia; Schlegelberger, Brigitte; Fabarius, Alice; Seifarth, Wolfgang; Spieß, Birgit; Wuchter, Patrick; Krause, Stefan; Kolb, Hans-Jochem; Neubauer, Andreas; Hossfeld, Dieter K; Nerl, Christoph; Gratwohl, Alois; Baerlocher, Gabriela M.; ... (2020). High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia, 34(8), pp. 2074-2086. Springer Nature 10.1038/s41375-020-0826-9
Michel, Christian; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Neubauer, Andreas; Lauseker, Michael; Krause, Stefan W; Kolb, Hans-Jochem; Hossfeld, Dieter Kurt; Nerl, Christoph; Baerlocher, Gabriela M.; Heim, Dominik; Brümmendorf, Tim H; Fabarius, Alice; Haferlach, Claudia; Schlegelberger, Brigitte; Balleisen, Leopold; Goebeler, Maria-Elisabeth; Hänel, Mathias; Ho, Anthony; ... (2019). Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica - the hematology journal, 104(5), pp. 955-962. Ferrata-Storti Foundation 10.3324/haematol.2018.206797
Haaß, Wiltrud; Kleiner, Helga; Weiß, Christel; Haferlach, Claudia; Schlegelberger, Brigitte; Müller, Martin C; Hehlmann, Rüdiger; Hofmann, Wolf-Karsten; Fabarius, Alice; Seifarth, Wolfgang; Baerlocher, Gabriela M.; Lämmle, Bernhard; Tobler, Andreas (2015). Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy. PLoS ONE, 10(6), e0129648. Public Library of Science 10.1371/journal.pone.0129648
Hanfstein, Benjamin; Lauseker, Michael; Hehlmann, Rüdiger; Saussele, Susanne; Erben, Philipp; Dietz, Christian; Fabarius, Alice; Proetel, Ulrike; Schnittger, Susanne; Haferlach, Claudia; Krause, Stefan W; Schubert, Jörg; Einsele, Hermann; Hänel, Mathias; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; ... (2014). Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica - the hematology journal, 99(9), pp. 1441-1447. Ferrata-Storti Foundation 10.3324/haematol.2013.096537
Hehlmann, Rüdiger; Müller, Martin C; Lauseker, Michael; Hanfstein, Benjamin; Fabarius, Alice; Schreiber, Annette; Proetel, Ulrike; Pletsch, Nadine; Pfirrmann, Markus; Haferlach, Claudia; Schnittger, Susanne; Einsele, Hermann; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F; ... (2014). Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. Journal of clinical oncology, 32(5), pp. 415-423. American Society of Clinical Oncology 10.1200/JCO.2013.49.9020
Fabarius, Alice; Leitner, Armin; Hochhaus, Andreas; Müller, Martin C; Hanfstein, Benjamin; Haferlach, Claudia; Göhring, Gudrun; Schlegelberger, Brigitte; Jotterand, Martine; Reiter, Andreas; Jung-Munkwitz, Susanne; Proetel, Ulrike; Schwaab, Juliana; Hofmann, Wolf-Karsten; Schubert, Jörg; Einsele, Hermann; Ho, Anthony D; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; ... (2011). Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood, 118(26), pp. 6760-8. Washington, D.C.: American Society of Hematology 10.1182/blood-2011-08-373902
